Defactinib

Drug Profile

Defactinib

Alternative Names: PF-04554878; PF-4554878; VS-6063

Latest Information Update: 07 Apr 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Pfizer; Verastem; Washington University
  • Class Antineoplastics; Benzamides; Pyrazines; Pyrimidines; Small molecules; Sulfones
  • Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mesothelioma; Non-small cell lung cancer
  • Phase I/II Ovarian cancer
  • Phase I Cancer; Pancreatic cancer; Solid tumours
  • Preclinical Breast cancer

Most Recent Events

  • 02 Apr 2017 Interim pharmacodynamics data from a phase I trial in Pancreatic cancer presented at the 2017 American Association for Cancer Research annual meeting (AACR-2017)
  • 26 Jan 2017 Phase I/II development is ongoing in Ovarian Cancer (Combination therapy, Late-stage disease, Recurrent, Second-line therapy or greater) in USA
  • 26 Jan 2017 Verastem initiates enrolment in a phase I/II trial for Ovarian cancer (Combination therapy, Late-stage disease, Metastatic, Recurrent, Second-line therapy or greater) in USA (NCT02943317)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top